T-705 (Favipiravir), WYE-28, Catalog: 2778

Alternate Names 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide; Avigan

Appearance Light yellow to yellow solid

CAS # 259793-96-9

Molecular Formula C₅H₄FN₃O₂

Molecular Weight 157.1

Purity ≥ 98%

Solubility DMSO (>15 mg/ml)

SMILES C1=C(N=C(C(=O)N1)C(=O)N)F

InChi InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

InChi Key ZCGNOVWYSGBHAU-UHFFFAOYSA-N

PubChem CID 492405

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

T-705 (Favipiravir) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. Recently, T-705 has been shown to give 100% protection against aerosol Ebola virus E718 infection in immune-deficient mice as well as inhibiting Ebola virus infection in cell culture. . It has been shown to inhibit SARS-CoV-2 in vitro.